Felzartamab is still an investigational drug that has not yet received regulatory approval, which poses a risk for investors and stakeholders regarding its eventual market success. The need for a ...

US-based biotechnology company Biogen has begun dosing in the Phase III TRANSCEND trial to assess felzartamab in adult kidney ...

Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated ...

Biogen has announced that it has initiated a late-stage study of felzartamab in adult kidney transplant recipients who have been diagnosed with late antibody-mediated rejection (AMR). The phase 3 ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMR AMR is a leading cause of kidney transplant loss, with ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMR AMR is a leading cause of kidney transplant loss, with ...